CD8A and neoplasm: Combining the previous results, we draw a preliminary conclusion that in NPC, BRD7 could downregulate PD-L1 expression, weaken the PD-1/PD-L1 axis, thereby inhibiting the exhaustion of CD8+ T lymphocytes and promoting the anti-tumor activity of T lymphocytes.